Overall Survival – Page 2

Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer

4 months ago talkbio0Tagged Clinical Trials, Gene Mutation, Inhibitor, Metastatic castration-resistant prostate cancer, Overall Survival, PARP1 gene, recombinational repair, TALAPRO-2, Talzenna, Xtandi

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations

Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study

4 months ago talkbio0Tagged Clinical Research, INAVO120, Inavolisib, Itovebi, Malignant neoplasm of breast, Overall Survival, PIK3CA mutation, Roche (company)

Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche

J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

4 months ago talkbio0Tagged chemotherapy-free regimen, Epidermal Growth Factor Receptor, Lazcluze, Mutation, Non-Small Cell Lung Carcinoma, Overall Survival, Phase III MARIPOSA trial, Rybrevant, Tagrisso

Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen

Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

6 months ago talkbio0Tagged disease treatment, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, HSCT-TMA, Improvement, Infrequent, Inhibitor, Lectin, MASP2 protein, human, narsoplimab, Overall Survival, Psychological inhibition

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

6 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

9 months ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

9 months ago talkbio0Tagged Advanced phase, AstraZeneca, durvalumab, ESMO24, Imfinzi, Imjudo, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma, Overall Survival, tremelimumab

AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

9 months ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial

ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns

9 months ago talkbio0Tagged belzutifan, Co., ESMO, LITESPARK-005 trial, Overall Survival, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial

KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

9 months ago talkbio0Tagged Chemoradiotherapy, Congress, Congress (U.S. Legislature), high-risk, Keytruda, Locally, Malignant tumor of cervix, Overall Survival, pembrolizumab

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024